Biogen IncNASDAQ:BIIB
- LAST PRICE223.2200
- TODAY'S CHANGE (%)1.6400 (0.7401%)
- Bid / Lots223.1600/ 1
- Ask / Lots223.3200/ 4
- Open / Previous Close221.7900 / 221.5800
- Day Range
- 52 Week Range
- Volume362,766
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BIIB |
|---|---|---|
| 09:32 ET | 15045 | 223.06 |
| 09:34 ET | 2213 | 221.665 |
| 09:36 ET | 3706 | 221.87 |
| 09:38 ET | 2801 | 221.79 |
| 09:39 ET | 2000 | 222.78 |
| 09:41 ET | 2921 | 222.1001 |
| 09:43 ET | 1255 | 223.08 |
| 09:45 ET | 1941 | 223.29 |
| 09:48 ET | 2900 | 224.41 |
| 09:50 ET | 904 | 224.74 |
| 09:52 ET | 5381 | 225.16 |
| 09:54 ET | 2000 | 224.47 |
| 09:56 ET | 300 | 224.04 |
| 09:57 ET | 2842 | 225.55 |
| 09:59 ET | 3570 | 225.77 |
| 10:01 ET | 3577 | 227.45 |
| 10:03 ET | 5632 | 227.67 |
| 10:06 ET | 7152 | 228.25 |
| 10:08 ET | 6764 | 227.3 |
| 10:10 ET | 5832 | 226.81 |
| 10:12 ET | 920 | 226.08 |
| 10:14 ET | 1600 | 225.92 |
| 10:15 ET | 800 | 225.24 |
| 10:17 ET | 5036 | 225.595 |
| 10:19 ET | 2346 | 225.61 |
| 10:21 ET | 692 | 226.0582 |
| 10:24 ET | 1113 | 225.925 |
| 10:26 ET | 800 | 225.11 |
| 10:28 ET | 250 | 225.57 |
| 10:30 ET | 400 | 225.44 |
| 10:32 ET | 900 | 224.905 |
| 10:33 ET | 1000 | 224.98 |
| 10:35 ET | 400 | 225.075 |
| 10:37 ET | 900 | 224.49 |
| 10:39 ET | 535 | 224.42 |
| 10:42 ET | 1422 | 224.24 |
| 10:44 ET | 1044 | 224.28 |
| 10:46 ET | 1702 | 223.645 |
| 10:48 ET | 3152 | 223.74 |
| 10:50 ET | 2357 | 223.37 |
| 10:51 ET | 1995 | 223.73 |
| 10:53 ET | 1678 | 223.4173 |
| 10:55 ET | 2443 | 223.33 |
| 10:57 ET | 725 | 223.06 |
| 11:00 ET | 763 | 223.17 |
| 11:02 ET | 6023 | 222.82 |
| 11:04 ET | 1751 | 222.95 |
| 11:06 ET | 8548 | 223.395 |
| 11:08 ET | 2506 | 223.8 |
| 11:09 ET | 2006 | 223.52 |
| 11:11 ET | 1060 | 223.585 |
| 11:13 ET | 1000 | 223.44 |
| 11:15 ET | 2192 | 223.41 |
| 11:18 ET | 1283 | 223.11 |
| 11:20 ET | 1571 | 222.91 |
| 11:22 ET | 100 | 222.83 |
| 11:24 ET | 4808 | 222.645 |
| 11:26 ET | 1200 | 222.805 |
| 11:27 ET | 800 | 223.12 |
| 11:29 ET | 300 | 223.13 |
| 11:31 ET | 4688 | 222.94 |
| 11:33 ET | 200 | 223.16 |
| 11:36 ET | 400 | 223.38 |
| 11:38 ET | 1227 | 223 |
| 11:40 ET | 521 | 223.08 |
| 11:42 ET | 500 | 222.94 |
| 11:44 ET | 2171 | 222.87 |
| 11:45 ET | 1368 | 222.935 |
| 11:47 ET | 1060 | 222.82 |
| 11:49 ET | 1684 | 223.11 |
| 11:51 ET | 621 | 223.4 |
| 11:54 ET | 1158 | 223.4 |
| 11:56 ET | 800 | 223.12 |
| 11:58 ET | 200 | 222.97 |
| 12:00 ET | 2054 | 223 |
| 12:02 ET | 700 | 222.98 |
| 12:03 ET | 483 | 222.955 |
| 12:05 ET | 2513 | 222.995 |
| 12:07 ET | 1577 | 223.1 |
| 12:09 ET | 595 | 223.03 |
| 12:12 ET | 930 | 223.19 |
| 12:14 ET | 600 | 222.92 |
| 12:16 ET | 1000 | 223.025 |
| 12:18 ET | 756 | 222.95 |
| 12:20 ET | 200 | 222.91 |
| 12:21 ET | 700 | 223 |
| 12:23 ET | 1553 | 223.25 |
| 12:25 ET | 600 | 223.21 |
| 12:27 ET | 1100 | 223.02 |
| 12:30 ET | 2465 | 223.58 |
| 12:32 ET | 800 | 223.54 |
| 12:34 ET | 719 | 223.61 |
| 12:36 ET | 3038 | 223.45 |
| 12:38 ET | 557 | 223.38 |
| 12:39 ET | 300 | 223.32 |
| 12:41 ET | 200 | 223.29 |
| 12:43 ET | 300 | 223.22 |
Today
Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights -- BIIB, from 12 minutes ago by Dow Jones
12 minutes ago by Dow JonesLevi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline, from 24 minutes ago by Dow Jones
24 minutes ago by Dow JonesDEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders, from 51 minutes ago by Dow Jones
51 minutes ago by Dow JonesBIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit, from 1 hour ago by Dow Jones
1 hour ago by Dow JonesShareholders that lost money on Biogen Inc. (BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More, from 2 hours ago by Dow Jones
2 hours ago by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Biogen Inc | 32.3B | 27.9x | -18.14% |
ICON PLC | 28.2B | 41.6x | +4.68% |
Moderna Inc | 46.6B | -8.0x | --- |
Grifols SA | 6.4B | 26.5x | --- |
IQVIA Holdings Inc | 41.2B | 31.7x | +46.62% |
Biontech SE | 20.0B | 165.6x | --- |
Company Information
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.
Contact Information
- Headquarters
- 225 Binney StreetCAMBRIDGE, MA, United States 02142
- Phone
- 781-464-2000
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Caroline Dorsa
- President, Chief Executive Officer, Director
- Christopher Viehbacher
- Chief Financial Officer, Executive Vice President
- Michael McDonnell
- Chief Human Resource Officer, Executive Vice President
- Ginger Gregory
- Executive Vice President, Chief Legal Officer
- Susan Alexander
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $32.3B |
|---|---|
Revenue (TTM) | $9.7B |
Shares Outstanding | 145.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.04 |
EPS | $8.00 |
Book Value | $102.14 |
P/E Ratio | 27.9x |
Price/Sales (TTM) | 3.3 |
Price/Cash Flow (TTM) | 19.0x |
Operating Margin | 17.21% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
